

Business Board Nomination to the Greater Cambridge Partnership Executive Board

To: Business Board

Meeting Date: 12 May 2021

Public report: Yes

Lead Member: Chair of the Business Board, Austen Adams

From: Director of Business & Skills, John T Hill

Key decision: No

Recommendations: The Business Board is recommended to:

- (a) Nominate Austen Adams, as the Chair of the Business Board, to be a non-voting co-opted member of the Greater Cambridge Partnership Executive Board;
- (b) Nominate Dr Andy Williams as the Business Board's substitute member of the Greater Cambridge Partnership Executive Board;
- (c) Note that the nominations at (a) and (b) above are subject to approval by the Greater Cambridge Partnership Executive Board;
- (d) Note that the Greater Cambridge Partnership will be asked to consider putting in place an arrangement to allow the substitute member to routinely attend Executive Board meetings in an informal non-voting capacity; and
- (e) Note that a further report will be brought to the Business Board on the issue of Business Board nominations to the Greater Cambridge Partnership Joint Assembly.

1. Purpose

- 1.1 To invite the Business Board to nominate Austen Adams, as the Chair of the Business Board, to be a non-voting co-opted member of the Greater Cambridge Partnership (GCP) Executive Board, and for Dr Andy Williams to be nominated as the substitute member.

2 Background

- 2.1 The former Greater Cambridge Greater Peterborough Local Enterprise Partnership (GCGP LEP) had nomination rights to the Executive Board of the GCP. The current representative for business on the Executive Board was appointed on an interim basis while the former LEP was being reconstituted as the Business Board.
- 2.2 The GCP have confirmed in correspondence that the Business Board may ask the Executive Board to replace the current business representative, who is not a member of the Business Board, by way of further nomination.
- 2.3 On 19th October 2020, an extraordinary Business Board meeting was convened, where the Business Board unanimously approved the following recommendations:
 - a) Nominate the Chair of the Business Board to be a non-voting co-opted member of the GCP Executive Board;
 - b) Note that the Chair of the Business Board will be co-opting Dr Andy Williams of AstraZeneca as a non-voting member of the Business Board; and
 - c) Propose to the GCP that it invite Dr Andy Williams to join the GCP Executive Board as a second non-voting member from the Business Board.
- 2.4 This was followed up at the GCP Executive Board meeting held on 10th December 2020, where the following decisions were made:
 - a) Ask the Business Board to reconsider this matter and make a nomination that is consistent with the GCP Executive Board's Standing Orders and Terms of Reference (as summarised in paragraph 4.4 of the report); and
 - b) Confirm that, subject to the above, it will consider whether it wishes to use the discretion available to the Chairperson and voting members (as summarised in paragraph 4.5 of the report) to allow both the Business Board nominee and the substitute member to attend the GCP Executive Board, should the case be made to do so.
- 2.5 The Chief Executive of the GCP wrote to the Chair of the Business Board on 11th January 2021, conveying the decisions made at the meeting on 10th December 2020.
- 2.6 Dr Andy Williams was until recently an active member of the GCP Joint Assembly. To retain his expertise and input, it is proposed to take up the suggestion that the GCP Executive Board be invited to consider whether both the Business Board's nominee and substitute should be allowed to routinely attend the meetings of the Executive Board.
- 2.7 The Business Board is being asked to formally approve the nomination to enable the GCP to approve this request at the next Executive Board meeting on 1st July 2021.
- 2.8 The Business Board has the right to nominate three representatives to the Joint Assembly, and the GCP Chief Executive has asked the Business Board to whether it proposes any change to the business representatives on the GCP's Joint Assembly. A report will be

brought to the next meeting of the Business Board regarding its representatives on the Joint Assembly.

Significant Implications

3 Financial Implications

3.1 None.

4 Legal Implications

4.1 None.

5 Appendices

5.1 None

6 Background Papers

6.1 Nomination to the Greater Cambridge Partnership Executive Board (Agenda Item 1.2, Business Board meeting on 19th October 2020
<https://cambridgeshirepeterboroughcagov.cmis.uk.com/Meetings/tabid/70/ctl/ViewMeetingPublic/mid/397/Meeting/2011/Committee/69/SelectedTab/Documents/Default.aspx>